Radiopharm Theranostics Limited (RADX)
NASDAQ: RADX · Real-Time Price · USD
0.9588
+0.0698 (7.85%)
At close: Nov 6, 2026, 4:00 PM EST
0.9355
-0.0233 (-2.43%)
After-hours: Nov 6, 2026, 7:02 PM EST
Radiopharm Theranostics Employees
Radiopharm Theranostics had 14 employees as of June 30, 2026. The number of employees did not change compared to the previous year.
Employees
14
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$635,723
Profits / Employee
-$2,814,177
Market Cap
11.93M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 14 | 0 | - |
| Jun 30, 2025 | 14 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| CytoMed Therapeutics | 42 |
| Lisata Therapeutics | 21 |
| SeaStar Medical Holding | 18 |
| IN8bio | 18 |
| CalciMedica | 15 |
| Kiora Pharmaceuticals | 13 |
| MetaVia | 8 |
| Intensity Therapeutics | 7 |
RADX News
- 4 days ago - Radiopharm Theranostics aligns with FDA on single Phase 3 trial for RAD101 - TheFly
- 4 days ago - Radiopharm Theranostics aligns with FDA on single Phase 3 trial for RAD101 - TheFly
- 4 days ago - Radiopharm Theranostics Announces Alignment with U.S. FDA on Single Pivotal Phase 3 Trial for RAD101 in Diagnosis of Brain Metastases - GlobeNewsWire
- 4 days ago - Radiopharm Aligns With FDA On Single Pivotal Phase 3 RAD101 Trial For Brain Metastases - Nasdaq
- 6 days ago - Radiopharm Theranostics Reports Business Update - GlobeNewsWire
- 9 days ago - Radiopharm Theranostics Earnings release: Q1 2027 - Filings
- 4 weeks ago - Radiopharm completes EOP2 meeting with FDA for RAD101 - TheFly
- 5 weeks ago - Radiopharm Theranostics Annual report: H2 2026 - Filings